Jeffrey M Leiden

Title: The Innovations of Jeffrey M Leiden

Introduction

Jeffrey M Leiden is a prominent inventor based in Weston, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic gene delivery systems. With a total of 5 patents to his name, Leiden's work has the potential to impact cardiovascular treatments and gene therapy.

Latest Patents

One of Leiden's latest patents involves the use of recombinant adeno-associated virus (rAAV) vectors to transduce cardiomyocytes in vivo. This innovative method entails infusing the rAAV into a coronary artery or coronary sinus, which has been shown to avoid detectable myocardial inflammation or myocyte necrosis. This makes rAAV a valuable vector for the stable expression of therapeutic genes in the myocardium, allowing for the delivery of genes that can induce or inhibit angiogenesis, stimulate or inhibit cell proliferation, and treat various cardiovascular conditions. Another notable patent focuses on a process for increasing the circulating levels of gene products in primates over an extended period. This process involves transforming muscle cells with an expression vector that encodes the desired gene product, driving expression in the muscle.

Career Highlights

Throughout his career, Jeffrey M Leiden has worked with various organizations, including Arch Development Corporation. His innovative approaches and research have positioned him as a key figure in the biotechnology sector.

Collaborations

Leiden has collaborated with notable professionals in his field, including Eliav Barr and Eric Svensson. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Jeffrey M Leiden's contributions to biotechnology and gene therapy are noteworthy. His innovative patents and collaborations highlight his commitment to advancing medical science and improving treatment options for cardiovascular conditions.